A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40mg) given as a single oral dose daily, in the treatment of panic disorder.
Panic Disorder
Phase 3
The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
December 2014